Myelodysplastic Syndrome Global Market Report 2024

The global myelodysplastic syndrome market has grown rapidly in recent years. It will grow from $2.3 billion in 2023 to $2.56 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing prevalence of myelodysplastic syndrome, growing awareness about myelodysplastic syndrome treatment, rising healthcare spending, government initiatives.

The global myelodysplastic syndrome market is expected to see rapid growth in the next few years. It will grow to $3.78 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to aging population, adoption of combination therapies, investment in hematologic research, personalized medicine. Major trends in the forecast period include innovative treatments for myelodysplastic syndrome, advancements in diagnostic tools and techniques, clinical trials, collaborative research.

The myelodysplastic syndrome (MDS) market is poised for growth, driven by the rising incidence of rare blood cancers. These uncommon blood cancers, categorized as hematologic malignancies, have a low occurrence rate within the population and originate in the cells of the bone marrow, lymph nodes, and other elements of the blood and immune system. MDS treatment is centered on managing the condition, improving blood cell production, and addressing related symptoms to prevent the progression of blood cancer in the bone marrow. For example, the Leukemia Foundation, a charitable organization in Australia, reported that more than 110,000 individuals are currently grappling with blood disorders as of June 2021. Moreover, it is anticipated that by 2035, the number of Australians affected by blood disorders will surpass 275,000. Hence, the increasing prevalence of blood cancers is a driving force behind the growth of the myelodysplastic syndrome (MDS) market.

The myelodysplastic syndrome (MDS) market is poised for expansion, driven by the expected surge in the number of bone marrow transplants. Bone marrow transplants are medical procedures in which damaged or diseased bone marrow is replaced with healthy stem cells to treat various conditions. MDS is characterized by bone marrow failure, which occurs due to the clonal expansion of somatically mutated hematopoietic stem cells. Bone marrow transplantation can effectively address MDS by replacing aberrant stem cells with healthy ones. For example, in 2021, a total of 5,073 unrelated and 4,276 related bone marrow and cord blood transplants were conducted in the United States and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR), as per data from the Health Resources and Services Administration, a US-based government agency. Consequently, the growth of the myelodysplastic syndrome market is being primarily fueled by the increasing number of bone marrow transplants.

The elevated expenses linked to myelodysplastic syndrome treatment can have a profound effect on the growth of the myelodysplastic syndrome (MDS) market, potentially limiting patient access and impeding overall market expansion. For instance, a report published by Springer Nature Group in November 2022 revealed that treatment costs have been notably high, particularly with regards to transfusions. In fact, these transfusions accounted for 81.3% of supportive care costs for patients transitioning to acute myeloid leukemia (AML) and 65.7% of supportive care costs. Consequently, the high cost of myelodysplastic syndrome treatment is posing a challenge to the market's growth.

Prominent companies within the myelodysplastic syndrome (MDS) market are dedicated to pioneering novel treatments to fortify their market presence. For instance, in July 2021, Genentech Inc., a US-based biotechnology firm, introduced Venclexta (venetoclax) in conjunction with azacitidine for the treatment of myelodysplastic syndrome (MDS) following approval from the US Food and Drug Administration (FDA). This approval encompasses the treatment of adult patients diagnosed with intermediate, high-risk, and very high-risk myelodysplastic syndromes (MDS). This groundbreaking therapy aims to expedite the development of medications intended to address severe or life-threatening conditions, with preliminary data suggesting substantial enhancements compared to existing treatments.

In November 2021, Merck & Co. Inc., a US-based pharmaceutical company, acquired Acceleron Pharma Inc. for an undisclosed amount. With this acquisition, Merck & Co. Inc. aims to expand its cardiovascular portfolio and further strengthen its commercial development strategy, addressing the urgent medical need to reach even more patients. Acceleron Pharma Inc. is a US-based clinical-stage biopharmaceutical company that develops medicines for myelodysplastic syndrome (MDS).

Major players in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

North America was the largest region in the myelodysplastic syndrome market in 2023. The regions covered in myelodysplastic syndrome (MDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the myelodysplastic syndrome (MDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Within the spectrum of myelodysplastic syndrome, various subtypes exist, including myelodysplastic syndrome with unilineage dysplasia, myelodysplastic syndrome with multilineage dysplasia, and myelodysplastic syndrome with ring sideroblasts. Myelodysplastic syndrome (MDS) with unilineage dysplasia is a specific classification within the range of MDS conditions. Treatment options for myelodysplastic syndrome encompass a range of drugs such as azacitidine, lenalidomide, decitabine, and deferasirox. Various treatment modalities are employed, including supportive therapy, growth factors, chemotherapy, and stem cell transplantation. These treatments can be administered through multiple routes, including oral, injectable, and others, and are delivered in diverse healthcare settings, such as hospitals, homecare, specialty centers, and more.

This report provides myelodysplastic syndrome market statistics, including myelodysplastic syndrome industry global market size, regional shares, competitors with a myelodysplastic syndrome market share, detailed myelodysplastic syndrome market segments, market trends and opportunities and any further data you may need to thrive in the myelodysplastic syndrome industry. This myelodysplastic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myelodysplastic syndrome (MDS) market consists of revenues earned by entities by providing experimental therapies, targeted therapies and blood transfusion. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelodysplastic syndrome (MDS) market also consists of sales of erythropoiesis-stimulating agents (ESAs) and immunomodulatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.